New weekly shot aims to shed pounds in obesity trial

NCT ID NCT07279194

Recruiting now Disease control Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a new drug called HDM1005, given as a weekly injection, to help people with obesity or overweight lose weight. It includes 825 Chinese adults who do not have diabetes. Participants receive either the drug or a placebo for 52 weeks, along with diet and exercise advice. The main goal is to see how much weight they lose after 40 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HDM1005 (a weekly injection for weight loss)
What this could lead to: If successful, this could provide a new weekly injection option for significant weight loss in people with obesity or overweight.
What could go wrong: This is a Phase 3 trial, but results may not apply to non-Chinese populations. Side effects from the drug are possible, and weight regain may occur after stopping treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY & OVERWEIGHT

Contacts and locations

Locations

Zhongshan Hoapital
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.